VEDBAEK, Denmark, Aug. 24, 2011 (GLOBE NEWSWIRE) -- In a multicenter study, Exiqon, in collaboration with LEO Pharma, Bispebjerg Hospital, Gentofte Hospital, Copenhagen University Hospital and University of Copenhagen, has identified promising diagnostic biomarkers of cutaneous T cell lymphoma (CTCL) to distinguish between malignant and benign inflammation - i.e. between CTCL and chronic diseases such as psoriasis, atopic dermatitis and eczema. The results have been published in the well-esteemed journal "Blood, Journal of the American Society of Hematology", which is available at: http://bloodjournal.hematologylibrary.org/content/early/2011/08/23/blood-2011-06-358382
